Association of hepatitis C with liver cirrhosis and hepatocellular carcinoma – a case study

Abstract

Hepatitis C virus infection (HCV) is endemic in many countries of the epatitis C virus infection (HCV) is endemic in many countries of the world including Georgia. Georgia has a high burden of HCV infection orld including Georgia. Georgia has a high burden of HCV infection with an estimated 5.4% of adult population (1,50,000) people have ith an estimated 5.4% of adult population (1,50,000) people have identified with HCV. According to NCDC (National Centre for Disease dentified with HCV. According to NCDC (National Centre for Disease Control and Public Health from May 2015 national HCV programme ontrol and Public Health from May 2015 national HCV programme have been launched, supported by the American company “Gilead” ave been launched, supported by the American company “Gilead” and the government of Georgia. Our main goal is to investigate and nd the government of Georgia. Our main goal is to investigate and manage the hepatocellular carcinoma. According to the study done anage the hepatocellular carcinoma. According to the study done from the patient at Infectious Disease AIIDS and clinical immunology rom the patient at Infectious Disease AIIDS and clinical immunology scientific research centre it has been found that in 57-year-old male cientific research centre it has been found that in 57-year-old male patient who was chronically infected with HCV, cirrhosis, the virus atient who was chronically infected with HCV, cirrhosis, the virus has been directly associated with the development of hepatocellular as been directly associated with the development of hepatocellular carcinoma. He was diagnosed as chronic hepatitis-c and liver cirrho- arcinoma. He was diagnosed as chronic hepatitis-c and liver cirrhosis (genotype 3a). Treatment with pegylated interferon and DAA (di- is (genotype 3a). Treatment with pegylated interferon and DAA (direct acting antivirals) for 6 months was continued. Treatment finished ect acting antivirals) for 6 months was continued. Treatment finished without side effects but after 6 months HCV RNA was detectable or ithout side effects but after 6 months HCV RNA was detectable or patient relapsed. In 2015, the patient was switched in elimination atient relapsed. In 2015, the patient was switched in elimination programme and antiviral treatment combined with interferon for 12 rogramme and antiviral treatment combined with interferon for 12 weeks. Sustained viral response developed 6 months after termina- eeks. Sustained viral response developed 6 months after termination of therapy. The alpha-fetoprotein is important tumor marker and ion of therapy. The alpha-fetoprotein is important tumor marker and was elevated around 583 as elevated around 583 μ/l. Ultrasound didn’t reveal any lesion but l. Ultrasound didn’t reveal any lesion but after MRI scan 3 fter MRI scan 3rdgrade hepatocellular carcinoma was confirmed. grade hepatocellular carcinoma was confirmed. Following 2015 every month patient has been assessed for liver func- ollowing 2015 every month patient has been assessed for liver function tests, total bilirubin, complete blood count, alpha-fetoprotein and ion tests, total bilirubin, complete blood count, alpha-fetoprotein and ultrasound investigation and as a result liver enzyme found to be ltrasound investigation and as a result liver enzyme found to be elevated. It’s crucial for every patient (end stage of liver disease) to levated. It’s crucial for every patient (end stage of liver disease) to undergo ultrasound investigations, liver function test for follow up. ndergo ultrasound investigations, liver function test for follow up.